Bal Pharma Quarterly Results for Trading Insights
In Sept 2025, Bal Pharma (BALPHARMA) reported revenue ₹75 Cr and net profit ₹1 Cr — revenue +1.4% YoY. Also explore BALPHARMA price movement history to track price trends across different timeframes.
BALPHARMA Quarterly Results — Revenue, Profit & EPS Highlights
Bal Pharma latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit BALPHARMA share price.
- Revenue of ₹75 Cr in Sept 2025 (-9.6% vs Mar 2025, +1.4% vs Sept 2024)
- Net Profit of ₹1 Cr in Sept 2025 (-80.0% vs Mar 2025, +0.0% vs Sept 2024)
- EBITDA of ₹7 Cr in Sept 2025 (-22.2% vs Mar 2025)
- Operating Margin of 8.0% in Sept 2025 (-1.0pp vs Mar 2025)
- Earnings Per Share of ₹0.45 in Sept 2025 (-86.8% vs Mar 2025)
Bal Pharma Quarterly Results — Revenue, EBITDA, Net Profit & EPS
BALPHARMA quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | Sept 2024 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 75 | 83 | 67 | 88 | 74 | -9.6% | 1.4% |
| Net Profit (₹ Cr) | 1 | 5 | 0 | 2 | 1 | - | - |
| EBITDA (₹ Cr) | 7 | 9 | 7 | 10 | 8 | - | - |
| EPS (₹) | 0.45 | 3.40 | 0.13 | 1.12 | 0.65 | - | - |
| Operating Margin (%) | 8.0% | 9.0% | 9.0% | 11.0% | 10.0% | - | - |
BALPHARMA Share Price Trend — 1-Year Movement Across Quarterly Results
Bal Pharma 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Compare with Bal Pharma valuation methods to assess whether the stock is under or overvalued.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
BALPHARMA vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Bal Pharma latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Sept 2025 |
₹450,643.09 Cr | 1891.3 | 14,875 | 3,125 | +10.8% | - | 21.0% | 145.5 |
|
Divis Laboratories
Sept 2025 |
₹179,470.03 Cr | 6858.0 | 2,860 | 689 | +7.1% | - | 24.1% | 264.1 |
|
Torrent Pharmaceuti…
Sept 2025 |
₹148,702.77 Cr | 4469.2 | 3,219 | 591 | +11.3% | - | 18.4% | 254.8 |
|
Cipla
Mar 2026 |
₹115,205.68 Cr | 1401.9 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 204.1 |
|
Dr Reddys Laborator…
Mar 2026 |
₹111,107.68 Cr | 1318.5 | 7,996 | 221 | -12.5% | -11.5% | 2.8% | 497.5 |
All amounts in ₹ Crores